Penumbra Inc — Form 8-K
Filed October 29, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 28/100
What the filing says
Penumbra reported Q3 2026 revenue of $410.1M (+15.6% YoY), with thrombectomy revenue $279.2M (+18.1%) and embolization/access $131.0M (+10.8%). Gross margin expanded to 68.3% (+0.5pp). Net income was $42.3M; the filing notes $7.1M in acquisition-related expenses. The company suspended full-year 2026 guidance and cancelled the earnings call due to the pending acquisition by Boston Scientific Corporation (counterparty: BSX), but no deal terms, price, or expected close date are disclosed in this filing.
Why this rating
Solid organic growth (+15.6%) and margin expansion are positive, but the pending $BSX acquisition dominates; deal size, terms, and timing absent here make impact assessment incomplete. Acquisition completion risk is material; interim results are routine. Relative to ~$9.7B market cap, Q3 results are normal-cycle performance.
See more from October 29, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.